Noninvasive low-level tragus stimulation attenuates inflammation and oxidative stress in acute heart failure.

Autor: Dasari, Tarun W., Chakraborty, Praloy, Mukli, Peter, Akhtar, Khawaja, Yabluchanskiy, Andriy, Cunningham, Madeleine W., Csiszar, Anna, Po, Sunny S.
Předmět:
Zdroj: Clinical Autonomic Research; Dec2023, Vol. 33 Issue 6, p767-775, 9p
Abstrakt: Purpose: Acute decompensated heart failure (ADHF) is associated with inflammation, oxidative stress, and excess sympathetic drive. It is unknown whether neuromodulation would improve inflammation and oxidative stress in acute heart failure. We, therefore, performed this proof-of-concept study to evaluate the effects of neuromodulation using noninvasive low-level tragus stimulation on inflammation and oxidative stress in ADHF. Methods: Nineteen patients with ejection fraction < 40% were randomized to neuromodulation 4 h twice daily (6–10 a.m. and 6–10 p.m.) (n = 8) or sham stimulation (n = 11) during hospital admission. All patients received standard-of-care treatment. Blood samples were collected at admission and discharge. Serum cytokines were assayed using standard immunosorbent techniques. Reactive oxygen species inducibility from cultured coronary endothelial cells exposed to patient sera was determined using a dihydrodichlorofluorescein probe test (expressed as fluorescein units). Results: Compared to sham stimulation, neuromodulation was associated with a significant reduction of circulating serum interleukin-6 levels (−78% vs. −9%; p = 0.012). Similarly, neuromodulation led to a reduction of endothelial cell oxidative stress in the neuromodulation group (1363 units to 978 units, p = 0.003) compared to sham stimulation (1146 units to 1083 units, p = 0.094). No significant differences in heart rate, blood pressure, or renal function were noted between the two groups. Conclusion: In this proof-of-concept pilot study, in acute decompensated heart failure, neuromodulation was feasible and safe and was associated with a reduction in systemic inflammation and attenuation of coronary endothelial cellular oxidative stress. Clinical trial registration: NCT02898181. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index